Begin main content

latanoprost

Last Updated: May 17, 2018
Result type: Reports
Project Number: SR0541-000
Product Line: Common Drug Review

Generic Name: latanoprost

Brand Name: Monoprost

Manufacturer: Laboratoires Théa

Indications: glaucoma and ocular hypertension

Submission Type: New

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: April 24, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

Key Milestones2

Call for patient input postedSeptember 26, 2017
Patient group input closedNovember 15, 2017
Clarification:

- No patient input submission received

Submission receivedOctober 25, 2017
Submission accepted for reviewNovember 08, 2017
Review initiatedNovember 09, 2017
Draft CDR review report(s) sent to applicantFebruary 01, 2018
Comments from applicant on draft CDR review report(s) receivedFebruary 12, 2018
Redaction requests from applicant on draft CDR review report(s) receivedFebruary 20, 2018
CDR review team's comments on draft CDR review report(s) sent to applicantMarch 09, 2018
Canadian Drug Expert Committee (CDEC) meetingMarch 21, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansApril 03, 2018
Embargo period ended and validation of redacted CDR review report(s) receivedApril 17, 2018
CDEC Final Recommendation issued to applicant and drug plansApril 24, 2018
CDEC Final Recommendation postedApril 27, 2018
Final CDR review report(s) and patient input postedMay 17, 2018

Tags

eye, glaucoma, open-angle, ocular hypertension, open-angle glaucoma; Glaucoma; ocular hypertension